Zobrazeno 31 - 40
of 160
pro vyhledávání: ''
Autor:
Xin Zhao, Hsien-Ming Hu, Erik Verschueren, John Jascur, Khyati N. Shah, Nevan J. Krogan, Jeffrey R. Johnson, Sourav Bandyopadhyay, John Von Dollen, Swati Kaushik, Gwendolyn M. Jang
Publikováno v:
Cancer Research. 78:3297-3297
Characterization of the genomic landscapes of cancer patients has provided valuable insights into the key oncogenic drivers and revolutionized the concept of precision treatment of patients. However, a key limitation is that targetable alterations ar
Publikováno v:
Cancer Research. 78:1522-1522
The recent FDA approvals of palbociclib, ribociclib, and abemaciclib in breast cancer validate cyclin-dependent kinases 4 and 6 (CDK4/6) as key therapeutic targets, and warrant investigations in other tumor types with frequently observed alterations
Autor:
Hossein Borghaei, Kathy Q. Cai, Vladimir Khazak, Mark A. Hitrik, Peter Makhov, Anna S. Nikonova, Rohan Brebion, Ilya G. Serebriiskii, Yanis Boumber, Brian L. Egleston, Eleanor Avril, Erica A. Golemis, Emmanuelle Nicolas, Alexander E. Kudinov, Alexander Y. Deneka
Publikováno v:
Cancer Research. 78:4452-4452
Musashi-2 (MSI2) is an RNA-binding protein that regulates mRNA translation. We recently established that MSI2 is elevated in a subset of non-small cell lung cancer (NSCLC) tumors upon progression and drives NSCLC metastasis, in part based on activity
Publikováno v:
Cancer Research. 78:2156-2156
A mechanism underlying anti-cancer drug resistance relies on the existence of cancer stem cells (CSCs). However, CSCs are either absent or are few in number in xenograft tumors and syngeneic mouse models. We developed new lung cancer mouse models wit
Publikováno v:
Cancer Research. 78:1836-1836
Activation of the epidermal growth factor receptor (EGFR) is involved in the oncogenesis of multiple cancers, particularly lung cancer. Current treatments are limited by the appearance of TKI resistance from secondary somatic mutations in the EGFR ge
Autor:
Clive Morris, Solène Marteau, Camille Leonce, Lionel Falchero, Pierre Saintingy, Gilles Clapisson, Maurice Pérol, Virginie Avrillon, Pierre Fournel, Sandra Ortiz-Cuaran, Emma Green, Luc Odier, Aurélie Swalduz, Séverine Martinez
Publikováno v:
Cancer Research. 78:937-937
Background: In EGFR-mutant non-small cell lung cancer (NSCLC), progression disease (PD) under 1st-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) is driven by the EGFR T790M mutation in about 50% of cases. This mutation is targeted with osimer
Autor:
Erica A. Golemis, Brian L. Egleston, Hossein Borghaei, Igor Astsaturov, Mackenzie Kramer, Tetyana V. Bagnyukova
Publikováno v:
Cancer Research. 78:3469-3469
Lung cancer is the leading cause of cancer related death in the US. Patients with advanced disease generally have a poor prognosis with a median survival of around 10 to 12 months with standard chemotherapy. In patients with non-squamous non-small ce
Autor:
Masaki Kashihara, Satoshi Hattori, Hisamichi Aizawa, Yuji Basaki, Akihiko Kawahara, Kazutaka Nakashima, Tetsuya Mitsudomi, Koichi Azuma, Mayumi Ono, Chizuko Yamamoto, Masayoshi Kage, Michihiko Kuwano
Publikováno v:
Clinical Cancer Research. 16:3163-3170
Purpose: Therapeutic responses of non–small cell lung carcinoma (NSCLC) to epidermal growth factor receptor (EGFR)–targeted drugs, such as gefitinib and erlotinib, are closely associated with activating EGFR mutations. The most common mutations a
Autor:
Angela M. Davies, David Sidransky, Jennifer Jaskowiak, Nir Peled, Daniel Ciznadija, Igor Astaturov, Haiying Cheng
Publikováno v:
Molecular Cancer Therapeutics. 17:A018-A018
Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality and prognosis remains poor despite the availability of numerous therapies. Integration of drug screening and sequencing in PDX models may allow for improved
Autor:
Luiz F. L. Reis, Manoel Cruz, Franciele Hinterholz Knebel, Joao Victor Machado Alessi, Anamaria A. Camargo, Andrea K. Shimada, Fabiana Bettoni, Marcelo V. Negrao, Artur Katz
Publikováno v:
Clinical Cancer Research. 24:B03-B03
Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. However, acquired resistance to osimertinib is also observed and the molecular mechanisms of resistance